Close Menu

NEW YORK – DermTech reported after the close of the market on Thursday that its fourth quarter revenues rose 31 percent year over year.

For the three months ended Dec. 31, 2020, the La Jolla, California-based developer of genomic melanoma tests posted $2.1 million in revenues, up from $1.6 million in Q4 2019.

Assay revenue soared 220 percent to $1.6 million from $500,000 a year ago. Meanwhile, contract revenue fell 49 percent to about $600,000 million in Q4 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.